Overgrowth syndrome with 2q37 translocation
oh-ver-grow-th sin-drohm with too-kew-thur-tee-sev-en trans-loh-kay-shun
Also known as: 2q37 deletion syndrome, Brachydactyly-mental retardation syndrome
At a Glance
What is Overgrowth syndrome with 2q37 translocation?
Overgrowth syndrome with 2q37 translocation is a rare genetic disorder characterized by excessive growth and developmental abnormalities. It primarily affects the skeletal system, leading to tall stature and skeletal malformations. The condition is caused by a chromosomal translocation involving the 2q37 region, which results in the overexpression of certain genes like NPPC. Over time, individuals may experience disproportionate growth, with some areas of the body growing faster than others. Early symptoms often include rapid growth and developmental delays, while later symptoms can involve joint problems and learning disabilities. Early diagnosis is crucial to manage growth and developmental issues effectively and to provide appropriate educational support. The condition can have a significant impact on family life, requiring ongoing medical care and support for developmental challenges. Prognosis varies, but with proper management, individuals can lead fulfilling lives. Daily life may involve regular medical check-ups, physical therapy, and educational interventions. Families may need to adapt their routines to accommodate medical appointments and therapy sessions. Support groups and counseling can be beneficial for affected families. Despite the challenges, many individuals with the condition achieve personal and academic success with the right support.
Medical Definition
Overgrowth syndrome with 2q37 translocation is a genetic disorder resulting from a chromosomal translocation at the 2q37 locus, leading to overexpression of the NPPC gene. Pathologically, this overexpression causes increased production of C-type natriuretic peptide, contributing to skeletal overgrowth and malformations. Histologically, affected individuals may exhibit abnormal bone growth patterns and cartilage development. The condition is classified under genetic overgrowth syndromes and is considered rare, with an estimated prevalence of 1 in 500,000. Epidemiologically, it occurs sporadically without a clear inheritance pattern. The disease course involves congenital onset with progressive skeletal abnormalities and developmental delays over time.
Overgrowth syndrome with 2q37 translocation Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Skeletal overgrowth manifests as an abnormal increase in bone length and size, leading to taller stature and disproportionate limb growth. This is caused by the overexpression of C-type natriuretic peptide (CNP), which stimulates endochondral ossification and bone growth. Over time, the excessive growth can lead to joint pain, mobility issues, and increased risk of fractures. Daily life can be significantly affected by these physical limitations, and management may include physical therapy and orthopedic interventions.
Developmental delay is observed as a lag in reaching cognitive, social, and motor milestones compared to peers. The underlying mechanism is not fully understood but may be related to genetic disruptions affecting neurological development. As the child grows, the delay can become more pronounced, impacting educational and social interactions. Early intervention programs, including speech and occupational therapy, can help mitigate these effects.
Facial dysmorphism is characterized by distinct facial features such as a broad forehead, flat nasal bridge, and prominent jaw. These features arise due to abnormal craniofacial development linked to genetic factors. Over time, these characteristics become more noticeable and may lead to social challenges or self-esteem issues. Supportive measures, including counseling and, in some cases, surgical correction, can be considered.
Common
Hypotonia presents as decreased muscle tone, resulting in floppiness and reduced strength. It is caused by neurological or muscular abnormalities associated with the genetic condition. As the child grows, hypotonia can lead to delayed motor skills and difficulties with posture and balance. Physical therapy and strength training exercises are often recommended to improve muscle tone and function.
Behavioral issues can include hyperactivity, attention deficits, and social interaction difficulties. These are thought to be linked to neurological and developmental disruptions caused by the chromosomal translocation. Over time, these issues can affect academic performance and peer relationships. Behavioral therapy and structured support can help manage these challenges effectively.
Hearing impairment may manifest as partial or complete hearing loss, affecting communication and language development. This can result from structural abnormalities in the ear or neural pathways involved in hearing. Without intervention, hearing impairment can lead to speech delays and social isolation. Hearing aids, cochlear implants, and speech therapy are potential interventions to improve hearing and communication skills.
Less Common
Cardiac anomalies can include structural heart defects such as septal defects or valve abnormalities. These arise from disruptions in cardiac development during embryogenesis. Over time, these anomalies may lead to symptoms like fatigue, shortness of breath, or heart failure. Regular cardiac monitoring and, if necessary, surgical interventions can help manage these conditions.
Seizures may occur as episodes of abnormal electrical activity in the brain, leading to convulsions or altered consciousness. The exact cause is not well understood but may be related to neurological abnormalities associated with the genetic condition. Seizures can vary in frequency and severity, impacting daily activities and quality of life. Antiepileptic medications and regular neurological assessments are essential for managing seizures effectively.
What Causes Overgrowth syndrome with 2q37 translocation?
The causative gene involved in overgrowth syndrome with 2q37 translocation is NPPC, located on chromosome 2q37. NPPC encodes the C-type natriuretic peptide (CNP), which plays a crucial role in endochondral ossification and skeletal growth. Mutations or translocations affecting NPPC can lead to its overexpression, disrupting the normal regulation of bone growth. This overexpression results in excessive signaling through the natriuretic peptide receptor B (NPR-B), leading to abnormal chondrocyte proliferation and differentiation. Consequently, this dysregulation causes skeletal overgrowth and malformations due to disrupted cartilage homeostasis. The altered signaling may also impact other cellular pathways, potentially affecting vascular and cardiac tissues. Neuroinflammation is not a primary feature of this condition, but immune responses may be indirectly affected by systemic changes. White matter degeneration is not typically associated with this syndrome, as the primary impact is on skeletal tissues. Symptoms manifest in a pattern related to the growth and development of bones, with disproportionate skeletal features being prominent. The variability in disease severity among patients can be attributed to the extent of NPPC overexpression and the presence of additional genetic or environmental modifiers. Some patients may exhibit more pronounced overgrowth due to additional genetic variations that exacerbate the phenotype. The specific chromosomal translocation breakpoint can also influence the degree of gene dysregulation. Furthermore, the timing of NPPC overexpression during development can affect the severity and range of symptoms. Overall, the combination of genetic, cellular, and developmental factors contributes to the diverse clinical presentation observed in affected individuals.
How is Overgrowth syndrome with 2q37 translocation Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in early childhood when growth abnormalities become apparent, often prompted by parental concern or routine pediatric assessments.
Clinicians look for signs of disproportionate skeletal growth and developmental delays. A detailed family history is crucial to identify any hereditary patterns or similar cases. Physical examination may reveal macrocephaly, tall stature, and dysmorphic facial features. This step helps to narrow down potential genetic syndromes and guides further testing.
X-rays and MRI are commonly used to assess bone structure and growth plate abnormalities. Specific findings may include advanced bone age and irregular growth patterns. These imaging results can confirm the presence of overgrowth and rule out conditions like Marfan syndrome or gigantism. Imaging helps to solidify the suspicion of a genetic cause for the overgrowth.
Hormonal assays, including growth hormone levels, are typically ordered. Elevated levels of C-type natriuretic peptide may be sought as a biomarker. Abnormal results often show elevated growth factors or hormonal imbalances. These results guide the clinician towards genetic testing to confirm the diagnosis.
Sequencing of the NPPC gene and analysis of chromosome 2q37 are performed. Translocations or deletions involving this region are identified. Positive results confirm the diagnosis of overgrowth syndrome with 2q37 translocation. Genetic findings are crucial for family counseling regarding recurrence risks and management.
Overgrowth syndrome with 2q37 translocation Treatment Options
This class includes drugs that inhibit excessive growth hormone activity. They work by blocking receptors or interfering with hormone synthesis. Somatostatin analogs like octreotide are commonly used. Clinical evidence shows they can reduce growth velocity but may not reverse existing overgrowth. Side effects include gastrointestinal disturbances and glucose metabolism alterations.
Techniques focus on improving joint mobility and muscle strength. The goal is to enhance functional ability and prevent contractures. Sessions are typically conducted twice weekly for several months. Outcomes are measured by improved range of motion and physical activity levels. Long-term benefits include better quality of life and reduced disability.
Surgery is indicated to control limb length discrepancies. The procedure involves the fusion of growth plates to halt further growth. Expected benefits include improved limb symmetry and function. Risks include infection, nerve damage, and incomplete correction. Post-operative care requires physical therapy and regular follow-up to monitor growth.
The team includes endocrinologists, geneticists, orthopedic surgeons, and physical therapists. Interventions focus on managing symptoms and improving quality of life. Psychosocial support strategies involve counseling and support groups for families. Education is provided on condition management and potential complications. Long-term monitoring includes regular assessments of growth and development.
When to See a Doctor for Overgrowth syndrome with 2q37 translocation
- Severe respiratory distress — this could indicate a life-threatening complication requiring immediate medical attention.
- Sudden loss of consciousness — this may signal a critical neurological event or severe metabolic imbalance.
- Uncontrolled seizures — these can lead to significant brain injury or other systemic complications if not promptly managed.
- Persistent or worsening pain in limbs — this could suggest complications related to skeletal overgrowth and warrants evaluation.
- Noticeable changes in growth patterns — significant deviations from expected growth may indicate progression of the condition.
- Frequent falls or coordination issues — these may reflect neurological involvement or musculoskeletal complications.
- Mild joint stiffness — monitor for any increase in stiffness or pain, which may require intervention.
- Occasional headaches — keep track of frequency and severity, and consult a doctor if they worsen.
Overgrowth syndrome with 2q37 translocation — Frequently Asked Questions
Is this condition hereditary?
Overgrowth syndrome with 2q37 translocation is typically not inherited but occurs due to a de novo chromosomal translocation. The probability of passing this condition to children is generally low unless a parent carries a balanced translocation. De novo mutations can occur, meaning they arise spontaneously in the affected individual. Carrier status implications are minimal unless a balanced translocation is identified in a parent. Genetic counseling is recommended to assess risks and discuss reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy varies and is influenced by the severity of symptoms and associated complications. Early intervention and management of symptoms can improve outcomes. Mortality is often related to complications such as respiratory or cardiac issues. Treatment can significantly enhance quality of life and potentially extend survival. Realistic expectations should include ongoing medical care and monitoring for associated health issues.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, genetic testing, and imaging studies. The time from first symptoms to diagnosis can vary but often takes several months due to the rarity of the condition. Specialists such as geneticists, endocrinologists, and orthopedists are commonly consulted. Delayed diagnosis may occur due to the overlap of symptoms with other conditions. A definitive diagnosis is confirmed through genetic testing identifying the 2q37 translocation.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and targeted molecular treatments as promising avenues. Novel approaches focus on regulating gene expression and managing growth abnormalities. Clinical trials can be found on ClinicalTrials.gov by searching for '2q37 translocation' or related terms. Patients should ask their doctor about eligibility for trials and potential benefits versus risks. New treatments may become available in the next few years as research progresses.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care due to skeletal abnormalities and joint issues. Educational adaptations may be necessary to accommodate learning difficulties. Social and emotional challenges include coping with physical differences and potential isolation. Family burden can be significant, requiring support and resources. Supportive therapies and adaptive equipment can greatly assist in daily functioning and quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype.
Moncla A, Missirian C, Cacciagli P et al. · Hum Mutat · 2007 · PMID: 17676597
- 2.Skeletal overgrowth syndrome caused by overexpression of C-type natriuretic peptide in a girl with balanced chromosomal translocation, t(1;2)(q41;q37.1).
Ko JM, Bae JS, Choi JS et al. · Am J Med Genet A · 2015 · PMID: 25728306
- 3.Genotype-Phenotype Correlation of 2q37 Deletions Including NPPC Gene Associated with Skeletal Malformations.
Tassano E, Buttgereit J, Bader M et al. · PLoS One · 2013 · PMID: 23805197
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-30